Experience reliable and high-purity performance with our CJC-1295 with DAC 5mg peptide from Top Shelf Peptides.

Long-Acting Growth Hormone-Releasing Hormone (GHRH) Research Peptide

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic Growth Hormone-Releasing Hormone (GHRH) analogue widely studied in growth hormone, recovery, body-composition, and longevity-related research.

Unlike shorter-acting GHRH peptides, the addition of the Drug Affinity Complex (DAC) allows CJC-1295 to bind to circulating albumin in the bloodstream, dramatically extending its active duration and maintaining elevated growth hormone signalling for prolonged periods.

Researchers investigating recovery pathways, lean-mass regulation, fat metabolism, and endocrine signalling are particularly interested in CJC-1295 with DAC because of its sustained growth hormone-releasing profile.

Bio Hackers Peptides supplies high-purity CJC-1295 with DAC 5mg within Australia with fast domestic dispatch and batch-verified purity testing.

Supplied as a lyophilised (freeze-dried) powder, CJC-1295 with DAC is intended strictly for laboratory and in-vitro research purposes only.

What Makes CJC-1295 with DAC Unique?

CJC-1295 with DAC is designed to mimic the activity of naturally occurring Growth Hormone-Releasing Hormone (GHRH), which stimulates the pituitary gland to release endogenous growth hormone.

The defining feature of this version is the:

Drug Affinity Complex (DAC)

The DAC component binds to albumin within the bloodstream, significantly increasing the peptide’s stability and duration of activity.

Researchers study this long-acting profile because it allows for:

• Sustained growth hormone signalling

• Extended endocrine activity

• Reduced administration frequency

• Longer-lasting IGF-1 elevation

• Prolonged anabolic signalling pathways

This differentiates it substantially from shorter-acting GHRH analogues such as CJC-1295 No DAC or Mod GRF 1-29.

How Researchers Study CJC-1295 with DAC

Growth Hormone & IGF-1 Signalling

Researchers investigate CJC-1295 with DAC for its apparent ability to stimulate:

• Natural growth hormone release

• IGF-1 production pathways

• Pituitary signalling activity

• Endocrine adaptation

• Recovery-related anabolic signalling

Its prolonged action profile has made it one of the most studied long-acting GH-releasing peptides in endocrine research.

Body Composition & Metabolic Research

One of the major areas of interest involves body-composition pathways.

Experimental models have investigated whether elevated GH signalling may influence:

• Lean-mass support

• Fat metabolism

• Visceral-fat pathways

• Nutrient partitioning

• Metabolic efficiency

• Energy utilisation

Researchers continue studying how long-duration GH elevation interacts with body-composition regulation.

Recovery & Tissue-Repair Research

CJC-1295 with DAC is also commonly studied in laboratory models involving:

• Muscle recovery

• Connective tissue support

• Joint recovery pathways

• Exercise adaptation

• Tissue-regeneration signalling

• Recovery-related cellular repair

Growth hormone signalling is heavily involved in recovery and regenerative biological processes, making this a significant focus area.

Healthy Ageing & Longevity Research

Researchers additionally investigate prolonged GH and IGF-1 pathway modulation in studies involving:

• Cellular repair

• Healthy ageing pathways

• Recovery adaptation

• Tissue resilience

• Sleep and recovery cycles

• Endocrine ageing research

The peptide’s sustained-release profile has made it particularly interesting in long-term endocrine and longevity studies.

DAC vs No DAC

Researchers commonly compare CJC-1295 with DAC against the No DAC variation.

CJC-1295 with DAC

Studied for:

• Long-duration activity

• Sustained GH elevation

• Reduced administration frequency

• Prolonged endocrine signalling

CJC-1295 No DAC

Studied for:

• Shorter GH pulses

• More physiological pulsatile signalling

• Greater protocol flexibility

• Reduced continuous receptor exposure

This distinction is one of the most important considerations in GH-peptide research.

Half-Life & Long-Acting Profile

Due to the DAC component, CJC-1295 with DAC has a substantially extended active duration.

Researchers commonly study it because of its reported:

• Approximately 6–8 day half-life

• Sustained endocrine activity

• Longer IGF-1 elevation windows

• Reduced dosing frequency in experimental protocols

Its extended-release profile is one of its defining characteristics.

Research Observations & Safety Context

Experimental observations involving CJC-1295 with DAC have generally reported mild effects within research settings.

Reported observations in experimental models have included:

• Temporary injection-site irritation

• Mild headaches

• Facial flushing

• Dizziness

• Water-retention-related signalling

Researchers continue investigating long-term endocrine and metabolic interactions.

Regulatory & Research Status

CJC-1295 with DAC remains an investigational compound in many jurisdictions.

It has not received broad approval from agencies including:

• U.S. Food and Drug Administration

• Therapeutic Goods Administration

for general therapeutic use.

Most currently available findings originate from:

• Experimental endocrine studies

• Preclinical investigations

• Growth-hormone pathway research

• Smaller-scale clinical investigations

Product Information

All products are sourced, tested, and dispatched entirely within Australia with fast domestic shipping and batch-specific Certificate of Analysis (CoA) verification available through the CoA Library or by scanning the QR code supplied with each product.

⚠ For in-vitro research and laboratory use only. Not for human consumption.

⚠ By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.